OXLUMO, a treatment for Primary Hyperoxaluria Type 1, has been funded across Canada and shown efficacy in reducing urinary oxalate levels.
1 report, 0 independent
Updated Jul 3
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
OXLUMO, a treatment for Primary Hyperoxaluria Type 1, has been funded across Canada and shown efficacy in reducing urinary oxalate levels.
Coverage
Newest first; wire copies grouped- Unknown outlet